Evidence map›Paper›PMID 30332461›Full record

ArticlePloS one2018

Serum levels of kisspeptin are elevated in critically ill patients.

Mark Luedde, Martina E Spehlmann, Hans-Joerg Hippe, Sven H Loosen, Sanchari Roy, David Vargas Cardenas, Mihael Vucur, Norbert Frey, Alexander Koch, Tom Luedde and 3 more

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Does kisspeptin act as a neuropeptide or as an adipokine in obese people?Journal of Taibah University Medical Sciences · 2022
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mark LueddeDepartment of Internal Medicine III, University Clinic of Schleswig-Holstein, Kiel, Germany.
Martina E SpehlmannDepartment of Internal Medicine III, University Clinic of Schleswig-Holstein, Kiel, Germany.
Hans-Joerg HippeDepartment of Internal Medicine III, University Clinic of Schleswig-Holstein, Kiel, Germany.
Sven H LoosenDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Sanchari RoyDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
David Vargas CardenasDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Mihael VucurDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Norbert FreyDepartment of Internal Medicine III, University Clinic of Schleswig-Holstein, Kiel, Germany.
Alexander KochDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Tom LueddeDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Christian TrautweinDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Frank TackeDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Christoph RoderburgDepartment of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0002-2245-6362

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMembers of the adipokine family such as resistin, adiponectin and omentin have recently been described as novel biomarkers with a diagnostic and prognostic role in the context of critically ill patients during intensive care unit (ICU) treatment. Kisspeptin represent another member of this family and has been shown to be closely correlated to different members of the adipokine family in manifold diseases. However, its role in critical illness and sepsis is currently unknown. MATERIALS AND

methodsKisspeptin serum concentrations were measured in 133 ICU patients admitted to the medical ICU. Results were compared with 36 healthy controls.

resultsKisspeptin serum levels were elevated in the serum of critically ill patients at admission to the ICU, when compared to healthy controls, and remained increased after 72 hours of ICU treatment. Notably, kisspeptin levels were independent of the presence of sepsis and etiology of critical illness. In line, serum concentrations of kisspeptin were not correlated to concentrations of inflammatory cytokines or established sepsis markers. Serum kisspeptin correlated inversely with the glomerular filtration rate. In contrast to the reported role of other members of the adipokine family, serum levels of kisspeptin were neither predictive for short term survival during ICU treatment nor for patients' overall survival. Kisspeptin levels did not correlate with other adipokines measured in serum, including leptin, resistin, ghrelin, or adiponectin.

conclusionsAlthough circulating kisspeptin levels were strongly elevated in ICU-patients, elevated kisspeptin levels were not predictive for an impaired patients' survival.

Indexed as

Critical IllnessAdolescentAdultAgedAged, 80 and overBiomarkersFemaleHumansIntensive Care UnitsKidneyKisspeptinsMaleMiddle AgedRenal Replacement TherapySepsisSurvival AnalysisBiomarkersKisspeptins

Identifiers

PMID30332461
PMCPMC6192635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.